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Abstract  
Objective 
To assess patterns of postnatal biventricular function and their relationship to 
prenatal and postnatal markers of disease severity in infants with congenital 
diaphragmatic hernia (CDH). To investigate clusters of micro RNA as 17-92 
expressed in pulmonary hypoplasia in patients with CDH. 
 
Study Design 
Observational case-control study of cardiac function in infants with CDH in the first 
5 days of life.  Systolic and diastolic function in the right (RV) and left (LV) ventricles 
were assessed using speckle tracking-derived global strain and tissue Doppler 
imaging of myocardial velocities. In another cohort of CDH, Bronchoalveolar 
aspiration (BAL) fluid was obtained and metabolomic analysis was run for micro 
RNA 17-92 cluster. Specifically miR17, miR18a, miR19a, miR19b, miR20a, miR92 
were analyzed. Correlation between cardiac function and prenatal 
observed:expected total fetal lung volume (TFLV), oxygenation index (OI), 
duration of intubation and length of stay were assessed.  
 
Results 
All measures of systolic and diastolic function were significantly reduced in the 
CDH group (n=25) compared to controls (n=20) at <48 hours, and improved by 72-
96 hours.  LV global systolic longitudinal strain (LV GLS) correlated with prenatal 
TFLV (r2 0.32, p 0.03), OI (r2 0.35, P<0.001), duration of intubation (r2 0.24, p 0.04), 
and length of stay (r2 0.4, p 0.006).  LV GLS at <48 hours was significantly lower in 
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CDH patients who did not survive and/or required ECMO compared to those who 
did not; -11.5 (5.3) % vs -16.9 (5.3) %, p 0.02. For the metabolomic analysis we 
found miR17, miE18a, miR19b, miR20a were found significantly higher in CDH 
(p<0.05) and miR19a lower (p<0.05). No significant correlation was found between 
miR92 expression and clinical outcomes.  
 
Conclusions 
Right and left ventricular function are impaired in the transitional period in infants 
with CDH.  Early left ventricular systolic function correlates with prenatal and 
postnatal markers of clinical disease severity and may be an important 
determinant of disease severity and therapeutic target in CDH.  These findings 
support regular assessment of cardiac function in CDH and investigational trials of 
targeted cardiovascular therapies. miR 17-92 cluster may represent a potential 
hallmark of PH in CDH however from our result doesn’t predict disease severity. 
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Introduction 
Congenital diaphragmatic hernia (CDH) affects 1 in 6000 live births and is 
characterized by herniation of the abdominal contents into the fetal thorax.  CDH 
remains a challenging condition for affected individuals and treating clinical teams.  
Despite advances in intensive care and surgical management over the past half-
century, CDH continues to cause significant mortality and morbidity (1,2). 
Pulmonary hypoplasia and pulmonary hypertension, due to abnormal pulmonary 
vascular development, play central roles in CDH pathophysiology (3–5).  There is 
also increasing recognition that the function of the heart may be a key 
determinant of CDH severity (6).   
 
The role of cardiac function in CDH pathophysiology 
Recent international treatment guidelines highlight the importance of assessing 
and treating cardiac function in CDH and randomized controlled trials are currently 
in progress to assess cardiovascular therapies  (7–9).  However, a missing piece of 
the CDH puzzle has been limited investigation of the timing, nature, and frequency 
of postnatal cardiac dysfunction in CDH and its relationship to clinical markers of 
severity.  
The advent of modern echocardiographic techniques, including strain analysis 
using speckle tracking echocardiography and tissue Doppler imaging (TDI), allows 
improved quantitative assessment of global and regional systolic and diastolic 
function (10,11).  Application of these techniques in infants with CDH may help 
reveal the mechanics of cardiac dysfunction and have implications for improving 
clinical management and outcomes.  
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The role of “omics” and pulmonary hypertension in CDH pathophysiology 
PH contributes to high mortality in CDH. A better understanding of the regulatory 
mechanisms underlying the pathology in CDH might allow the identification of 
prognostic biomarkers and potential therapeutic targets (miR CDH). 
Recent studies provide evidence of abnormal patterns in proliferation, apoptosis 
and cell differentiation, and altered expression of growth and transcription factors 
and genes reported to be involved in the etiology of pulmonary hypoplasia in CDH 
(12). These mechanisms seem to regulated from clusters of mirco RNA. MicroRNAs 
(miRNAs, miRs) are a large group of noncoding small RNAs about 22 nucleotides 
in length. miRs mainly act accelerating the degradation of messenger RNAs or to 
repress the translation, thus, negatively regulating the expression of target genes 
(13). Regulating up to around one third of all miRs in human, miRs have been 
identified to play important regulatory roles in a wide array of pathological 
processes and embryonic organ morphogenesis (14–16). The functions of miRs in 
lung development are subjects of many investigations (13,15,17,18). For example, 
the miR-17-92 family has been reported to regulate early lung development by 
promoting proliferation and inhibiting differentiation of lung epithelium. The 
deletion of miR-17- 92 cluster in mice resulted in immediate postnatal death with 
smaller embryos and hypoplastic lungs (19,20), while overexpression of this 
cluster leads to severe developmental defects with high proliferation and 
undifferentiated phenotype of lung epithelial progenitor cells (21). 
 
Aims 
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This study aimed to assess patterns of ventricular function in infants with CDH in 
the first week of life and to investigate their relationship with pre-and post-natal 
measures of disease severity.  
For the purpose of this thesis, we investigated in a separate group of neonates 
with CDH, the miR 17-92 cluster in the lungs to explore possible predictors of 
pulmonary hypertension severity in CDH. 
 
Methods 
Study design and setting 
The study included two centers. For the “ventricular function” evaluation patients 
were recruited at the Royal Hospital for Children, Glasgow and for the genetic 
analysis of miRNA patients were enrolled at the Bambino Gesù Hospital. Both are 
a regional neonatal surgical center and national extra-corporeal membrane 
oxygenation (ECMO) center.   
 
Demographic data for both groups 
Sex, gestation, birth weight, and mode of delivery were collected from the 
electronic patient record.  In the CDH group additional characteristics, treatment, 
and outcome data were obtained; side and size of defect (22), age at repair, use 
of patch, stomach and liver position at time of surgery, cardiovascular therapies 
and ECMO, duration of intubation (DINT) and neonatal length of stay (LOS) in 
survivors, oxygen requirement at discharge, and survival to neonatal discharge. 
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CDH cases were managed by a multi-disciplinary team in both centers according 
to an institutional treatment protocol, in accordance with international guidelines 
(23).  Briefly, this incorporates a “gentle” ventilation strategy minimizing 
volutrauma and barotrauma, targeted use of pulmonary vasodilators (inhaled 
nitric oxide and intravenous sildenafil) based on clinical and echocardiographic 
evidence of clinically significant pulmonary hypertension, and selective use of 
cardiotropes (milrinone, dopamine, and epinephrine) based on clinical and 
echocardiographic evidence of impaired cardiac function and systemic blood flow.  
Prostaglandin E1 is used to maintain ductal patency in the presence of 
systemic/suprasystemic pulmonary artery pressures, right ventricular dysfunction 
and a closing arterial duct.  ECMO is employed in selected cases to treat respiratory 
and cardiovascular compromise resistant to optimized medical therapy which is 
considered reversible.   
Study population, analysis and results will be presented describing firstly the 
“ventricular function group” (Section 1) which represents the main topic of this 
study. Separately, in a second section, we will describe the “omics group” (Section 
2). 
 
Section 1: Ventricular function group 
This retrospective case-control study was conducted at the Royal Hospital for 
Children, Glasgow. 
 
Study population 
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CDH group:  Infants with CDH, both inborn and outborn, admitted to the study 
center between January 2015 and January 2018 were considered for inclusion.  
Cases with significant associated congenital anomalies (significant cardiac 
anomalies other than ventricular septal defect, major chromosomal anomalies e.g. 
chromosomal trisomies), were excluded.  Prenatally diagnosed CDH cases 
underwent routine magnetic resonance imaging (MR) at 25-28 weeks gestation to 
measure observed-to-expected ratio of total fetal lung volume (O:E TFLV), as 
previously described (24,25).  MR data was used in preference to  ultrasound lung-
head ratio based on prior reports of improved predictive value of MR lung volume 
assessment in CDH (26). 
Control group 
A control group of infants with esophageal atresia treated during the study period 
was identified from electronic records. These infants routinely have 
echocardiographic assessment in the first 48 hours of life and formed a 
convenience sample for comparison with CDH cases.  Only infants who were 
breathing spontaneously in air, without clinical or echocardiographic evidence of 
pulmonary hypertension or congenital cardiac anomaly (including ventricular 
septal defect), were included. 
 
Echocardiography data 
Only for the ventricular function group, echocardiographic data were collected by 
the study researchers (NP, EA) according to an institutional protocol using a GE 
Vivid E9 (GE Medical Systems, Milwaukee, WI) with a 6 MHz probe and analyzed 
using EchoPac software incorporating QLab (EchoPAC version 202; GE Medical 
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Systems, Milwaukee, WI).  Post-acquisition analysis was performed by a single 
observer (ACM).   The first echocardiogram (<48 hours of age) was analyzed in all 
CDH cases and controls.  Follow-up echocardiograms at 72-120 hours was also 
analyzed in CDH cases, but were not available for controls. 
 
Cardiac function in the right ventricle (RV) and left ventricle (LV) were assessed 
using pulsed wave tissue Doppler imaging (TDI), myocardial strain derived from 
speckle tracking echocardiography, fractional area change (FAC), and Doppler flow 
across the atrioventricular valves (AV).   
  
TDI velocities in systole (s’) and diastole (e’) were measured in the basal 
myocardium of the LV and RV lateral walls and the interventricular septum from 
an apical 4-chamber view, as previously described (27).   
 
STE analysis was used to assess systolic strain (myocardial shortening) from gray-
scale 2-dimensional (2D) cine-loops, acquired in the 4-chamber apical view (for 
longitudinal strain) and 2-chamber short axis at mid-ventricle level (for radial and 
circumferential strain, LV only).  Images with an optimized frame rate:heart rate 
ratio were selected (28).  Regions of interest were traced within the endocardial 
border and adjusted manually to optimize tissue-tracking.  Peak global longitudinal 
(GLS, in the LV and RV) circumferential (GCS, LV only) and radial strain (GRS, LV 
only) were obtained. 
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FAC, a global measure of ventricular function was calculated as the percentage 
change in ventricular area using end systolic area (ESA) and end diastolic area 
(EDA) measurements obtained by manually tracing the internal contours of the 
endocardial border from apical 4-chamber images (29).  AV valve velocities in early 
(E) and late (A) diastole were measured from pulsed wave Doppler waveforms 
across the mitral and tricuspid valve, as measures of diastolic function.  
 
Pulmonary artery pressure (PAP) was assessed using patent ductus arteriosus 
(PDA) flow, and tricuspid regurgitation velocity (TR) when present.  A pulsed wave 
Doppler waveform was obtained in the PDA from which the velocity-time integer 
of left-to-right and right-to-left flow components was manually traced and a ratio 
calculated (VTIL-R) to quantify PAP.  Maximal velocity of TR was assessed by pulsed-
wave Doppler and inserted into a modified Bernoulli equation to derive estimated 
peak RV systolic pressure (RVSPEST) (30).  Using these measures PAP was also 
classified as <2/3rd systemic blood pressure, 2/3rd systemic-to-systemic blood 
pressure, or > systemic blood pressure (31).  All Doppler-derived data were 
averaged over five consecutive cardiac cycles.  Oxygenation index (OI) at the time 
of initial echocardiogram was calculated using the formula :(% inspired oxygen x 
mean airway pressure x 100) / Arterial PO2.  Arterial PO2 was obtained from arterial 
blood gases obtained from right radial or umbilical artery.  
 
Section 2: Omics group 
Neonates were enrolled at Bambino Gesù Children’s Hospital and patients were 
selected prospectively and case-control. 
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Study population 
CDH group: Infants with CDH, both inborn and outborn, admitted to the study 
center between January 2015 and January 2018 were considered for inclusion.  
Same inclusion and exclusion criteria of the ventricular function group were 
applied. 
Control group 
A control group of infants with esophageal atresia treated during the study period 
was identified. 
 
Omics Analysis 
All patients, intubated, underwent bronchoalveolar lavage (BAL) fluid suction 
within the first 48 hours of life. 1ml/kg of saline solution was administered through 
the endotracheal tube and after three ventilation cycles was extracted. BAL were 
stored at -80°C and then analyzed for the study of the mi-RNA 17-92 cluster. The 
RNA extraction were vortexed and centrifuged for 5 minutes at 1250 r/min.  
Adequate dosage was assessed through spectrophotometry. RNA was extracted 
with the miRNeasy Mini Kit (Qiagen), for the Real-Time PCR. QuantiTect Reverse 
Transcription Kit (Qiagen) was used to obtain RNA transcription, and amplified 
with SYBR Green PCR Master Mix (Qiagen). From the 17-92 cluster we analyzed 
the following miR: mi-RNA 16, mi-RNA 17, mi-RNA 18, mi-RNA 19A, mi-RNA 19b, 
mi-RNA 20a e mi-RNA 92. U6 snRNA was used as control. REAL-time PCR was 
performed through the StepOnePlus TM real-time machine (Applied Biosystems).  
 
           Statistical Analysis 
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Data were summarized as median (range) or mean (standard deviation).  Global 
strain and FAC data from CDH cases and controls at <48 hours were compared 
using unpaired T test.  TDI and AV valve Doppler data were not available for 
controls, instead comparison was made to existing normative published data (32).  
CDH data at <48 hours and 72-120 hours were compared using paired T tests.  
Correlation was assessed between measures of cardiac function at <48 hrs and O:E 
TFLV, OI, DINT, LOS, and LV size using LV EDA.  Chi-square or Fisher’s exact tests 
were used to compare categorical data.  Cardiac function parameters in CDH group 
at < 48hrs were compared between survivors vs. non-survivors, ECMO vs. no 
ECMO, and the combination of these (non-survival+/-ECMO). miRs were 
compared between the two groups using unpaired T test.  Correlation was 
assessed between measures of miRs and LHR, OI, DINT, LOS, survivals or death and 
need of ECMO or not. Analysis was performed using Prism 7 (GraphPad Software, 
La Jolla, CA, USA).  A p value < 0.05 was considered significant.  Statistical support 
was provided by an experienced statistician.  Institutional ethical approval was 
provided for data analysis and publication. 
 
Results 
Section 1: Ventricular function group 
Demographic and treatment data 
Twenty-seven CDH cases and 20 controls were included. Two CDH cases were 
excluded due to insufficient echocardiographic images for analysis. There were no 
significant differences in demographic data between CDH cases and controls, 
Table 1.  
 16 
CDH characteristics, treatment, and outcome data are provided in Table 1.  
Prenatal MRI data at weeks gestational age was available for 15 (60%) CDH cases, 
mean MRI O:E TFLV, was 38 (14)%.  Twenty-two CDH cases (81%) underwent 
surgical repair at a median (range) of 9 (2-20) days.  Of these 14 (63%) required 
patch repair.  Seventeen CDH cases (68%) survived to discharge.  For survivors, 
median (range) duration of intubation was 23 (4-72) days, and length of stay was 
41 (17-164) days. 
Eight (32%) cases received ECMO.  Twenty-three CDH cases (92%) received 
cardiotropes.  The same proportion received inhaled nitric oxide, of whom 16 
(64%) also received intravenous sildenafil. 
 
Cardiac function and PAP data at <48 hours and 72-120 hours 
STE-derived global strain analysis was performed in all cases at <48 hours, but only 
for GLS parameters at 72-120 hours (insufficient images for GCS and GRS at 72-
120 hours).  TDI velocities were measurable in 18 CDH cases, and AV Doppler 
velocities in 11 cases, at both time points.  
 
In the first 48 hours of life, all global strain parameters were significantly reduced 
in the LV (GLS, GCS and GRS) and RV (GLS) compared to controls, Table 2.  TDI 
systolic (s’) and diastolic (e’) velocities in the RV, septum and LV, as well Doppler 
inflow velocities (TV E, MV E) were also significantly reduced compared to existing 
normative data.  PFO shunt was left-to-right in 16 (59%) CDH cases, right-to-left or 
bidirectional in five (19%) cases, or no shunt seen in 6 (22%) cases.  There were no 
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significant differences in RV or LV strain or FAC parameters between infants with 
left-to-right PFO shunt versus those with bidirectional or right-to-left shunt.  
 
Cut off values for abnormal RV and LV GLS at < 48 hours of life were determined 
as one standard deviation below the mean from control data; RV GLS cut off ≤-
14%, LV GLS cut off ≤=-16%.  According to these definitions, seven CDH cases (28%) 
had normal RV and LV GLS, four CDH cases (16%) had abnormal RV GLS only, five 
(20%) had abnormal LV GLS only, and nine (36%) had abnormal LV and RV GLS, 
Figure 1. 
 
At 72-120 hours of age, RV-GLS and LV-GLS increased significantly, compared to 
<48 hours of age.  LV FAC and LV EDA were significantly reduced in the CDH group 
at <48 hours compared to controls and to CDH cases at 72-120 hours, Table 2.  LV 
EDA at <48 hours did not correlate with STE measures of LV function. 
 
TR was measurable in 16 (64%) of cases.  Twenty-one CDH cases (84%) had a PDA 
at <48 hours of age, in which flow was bidirectional in 17 (68%) cases, right-to-left 
in three cases (12%), and left-to-right in one case (4%).  Mean (SD) RVSPEST was 50 
(18) mmHg, and mean (SD) PDA VTIL:R was 1.35 (2.1). Measures of PAP were not 
significantly different at <48 vs 72-120 hours of age.  PAP at <48 hours was 
classified as <2/3rd systemic blood pressure in 3 cases, 2/3rd systemic-to-systemic 
blood pressure in 12 cases, and > systemic blood pressure in 11 cases. 
 
Cardiac function, PAP and illness severity 
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MRI O:E TFLV correlated significantly with LV GLS (r2 0.32, p=0.03, Figure 2a) and 
TDI LV E’ (r2=0.45, p=0.02) at <48 hours, but not with measures of RV function, 
RVSPEST or PDA VTIL:R.   There were no significant differences in cardiac function 
parameters (FAC and global strain measures) between cases based on PAP 
category. 
 
LV GLS at < 48 hours of age correlated significantly with OI (r2 0.35, P<0.001), DINT 
(r2 0.24, p=0.04) and LOS (r2 0.4, p=0.006), Figures 2b and 2c.   
 
LV GLS at < 48hours of age was significantly lower in CDH cases with the combined 
outcome of death+/-ECMO versus survivors/no ECMO: -11.5 (5.3) % vs. -16.9 (5.3) 
%, p=0.02.  LV GLS in CDH survivors vs. non-survivors was 15.4 (6.1) % vs. -11.6 
(4.5) %, p=0.11, and in non-ECMO vs ECMO CDH cases was -15.6 (5.4) % vs. -11.7 
(6.1) %, p=0.15.   
 
Section 2: Omics group 
20 neonates with CDH were enrolled, 3 were excluded for insufficient BAL fluid. 
17 controls with OA were included too. No statistical differences were found 
between the two groups for GA, weight, and sex (GA 37,4 +2 vs 38,2 +1,8, p=0,23; 
weight at birth 2.770 + 599 vs 2.965 + 470, p=0,33). Of these 20 patients, 16 
survived, 6 underwent ECMO. Of 4 non survivors, 2 underwent ECMO. 
For the analysis of the 17-92 cluster in the BAL fluid in CDH patients compared to 
controls we found a significant increase of miR16, miR18a, miR17, miR19b, miR20a 
(t-test ; CDH vs control; p< 0,05) (Figure 4 a,b,c, and d) and a significant decrease 
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of miR19a in the CDH group (Figure 4 e) and no statistical difference was found for 
miR92.  
 
Discussion 
We assessed cardiac function in the early postnatal period in infants with CDH and 
a control population using a panel of echocardiographic techniques including 
strain analysis and tissue Doppler imaging.  There is growing experience of these 
techniques in newborn infants and recognition of their benefits over traditional 
geometric measures of cardiac function (33).  Our findings provide new insights 
into patterns of cardiac dysfunction in CDH, their relationship to disease severity, 
and may inform improvements in clinical management and outcomes.  
 
Patterns of ventricular dysfunction after birth in CDH 
RV and LV dysfunction were present in CDH patients in the first 48 hours of life.  
RV dysfunction was predominantly diastolic in nature, consistent with previous 
reports (34,35).  RV diastolic dysfunction likely results from the acute and 
prolonged increase in afterload (PVR) after birth, due to functional and structural 
abnormalities of the pulmonary vasculature characteristic of CDH (36). 
 
Postnatal LV dysfunction was characterized by impairment of both systolic 
function (in longitudinal, circumferential and radial dimensions) and diastolic 
relaxation.  This global LV dysfunction during the transition from fetal to postnatal 
life may have four etiological factors;  First, fetal LV hypoplasia due to mechanical 
compression and reduced LV blood flow, the latter resulting from reduced 
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pulmonary venous return and altered ductus venosus flow (37–39).  Second, 
reduced postnatal LV filling due to persistently elevated pulmonary vascular 
resistance and reduced pulmonary blood flow.  Third, transmission of RV 
dysfunction to the LV, via mechanisms of ventricular interdependence including 
the shared septum, muscle fibres, and pericardium (40).  Fourth, the acute 
increase in afterload at birth as the LV takes over as the systemic ventricle and the 
placenta is removed from the circulation. 
 
Early cardiac dysfunction appears to be common in CDH.  Using cut-off values for 
longitudinal global strain derived from control group data, we observed 
dysfunction in over two-thirds of cases and biventricular dysfunction in one-third 
of cases in this cohort. 
 
RV and LV function improved significantly within the first week of life, as we have 
previously observed (41,42).  It was not possible within this study to unravel the 
relative contributions of time, endogenous pathways and exogenous therapies, 
however the potential for improvement in function may be important when 
making therapeutic decisions, including continuing intensive care support, 
cardiovascular therapies, and timing of surgery, as discussed later. 
 
Ventricular dysfunction and CDH severity 
LV systolic function correlated with  fetal lung volumes, an established marker of 
pulmonary hypoplasia and predictor of illness severity (43,44).  Fetal left 
ventricular hypoplasia in CDH is also more severe in infants with smaller prenatal 
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lung volumes (45).  Taken together these findings support the theory that 
postnatal LV dysfunction has prenatal origins linked to the severity of pulmonary 
and LV hypoplasia.  
 
We also observed a relationship between early LV systolic function and clinically 
relevant postnatal outcomes.  LV function was worse in infants who died and/or 
received ECMO, and demonstrated a significant negative association with 
oxygenation index, duration of intubation and length of stay in survivors.  Similarly, 
Altit et al observed reduced LV longitudinal strain in infants with CDH who received 
ECMO compared to those who did not (46).  These consistent findings suggest that 
LV function may be a primary determinant of disease severity in CDH, rather than 
simply a secondary consequence.  Furthermore, early LV function may be an 
important parameter for future inclusion in early predictive algorithms in CDH 
(47).   
 
LV dysfunction may plausibly destabilize infants at the transition to postnatal life 
by reducing systemic blood flow and oxygen delivery, contributing to tissue 
hypoxia and acidosis.  This in turn may lead to a vicious cycle of worsening cardiac 
function and pulmonary vasoconstriction.   Further investigation of the 
relationship between early cardiac function and outcome in CDH in larger cohorts, 
such as CDH registries, is now warranted (48).    
 
Early RV function did not correlate with clinical outcomes, in contrast to a prior 
investigation (41).  One possible explanation may be a change in management 
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approach in the current study cohort toward earlier use of pulmonary vasodilators 
and cardiotropic support.  The potential of this early, targeted treatment approach 
to alter outcome merits further investigation. 
 
Of note, PAP in the first 48 hours did not correlate with fetal lung volume or clinical 
outcomes, consistent with previous reports (41,46).  This may be due to the fact 
that most  normal infants have raised PAP after birth, but also highlights the 
challenge of measuring PAP accurately using echocardiography, and the 
importance of assessing cardiac function directly in addition to PAP (49). 
 
An additional observation was the variable patterns of inter-atrial flow.  Though 
shunt direction was not associated with cardiac function in this limited cohort, our 
findings highlight the importance of assessing intra-cardiac shunts in CDH patients 
to appreciate their potential influence on gas exchange and systemic oxygenation. 
 
Implications for assessment and treatment of CDH 
Recent CDH treatment guidelines from North America and Europe note the role 
for echocardiographic assessment of routine PAP and cardiac function (7,8).  
Based on our findings, both RV and LV function should be assessed regularly 
starting from the first days of life to detect early dysfunction and monitor response 
to therapy.  Future consensus guidelines should include recommendations for the 
timing and techniques to assess cardiac function in CDH. 
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Identifying infants at greatest risk of cardiac dysfunction may allow preventative 
or anticipatory management.  Our results suggest that MR fetal lung volumes 
might be useful to stratify infants most likely to develop LV dysfunction.  Kinsella 
et al have recently proposed that routine measurement of fetal LV size may predict 
postnatal LV function (6).   
 
A possible approach to minimize postnatal cardiac dysfunction may be delayed 
umbilical cord clamping combined with lung recruitment to maintain circulating 
volume, improve pulmonary blood flow and optimize left ventricular function (50).  
Further investigation is needed to assess whether this approach is feasible and 
beneficial in CDH. 
 
Improved assessment and understanding of RV and LV function in CDH can guide 
rational, targeted selection of cardiovascular therapies.  RV diastolic dysfunction 
is an indication for pulmonary vasodilatation to reduce afterload, combined with 
lusitropic support to improve diastolic function.  LV dysfunction, meanwhile, 
should benefit from afterload reduction by systemic vasodilatation and inotropic 
support.  One agent with these combined properties is milrinone, a phospho-
diesterase 3 inhibitor (51).  Our findings add further support to a randomized 
controlled trial of milrinone in CDH which is now in progress (9). 
 
Current treatment guidelines advocate fluid bolus as first line therapy for systemic 
hypotension in CDH.  However, if low blood pressure is due to LV dysfunction then 
inotropes may be more appropriate, such as low dose epinephrine administered 
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in our cohort.  Systemic vasoconstrictors increase LV afterload and may 
exacerbate LV dysfunction, this may explain the variable response to vasopressin 
in CDH (52).  
 
The role of pulmonary vasodilators in the setting of LV dysfunction in CDH is 
unclear.  There is a theoretical concern that by increasing pulmonary blood flow 
and LV preload they may exacerbate LV diastolic dysfunction and pulmonary 
venous hypertension (53–56).  Conversely, by improving RV function they may 
indirectly improve LV performance via mechanism of ventricular 
interdependence.  The CoDiNOS trial, a current multi-center randomized 
controlled trial of intravenous sildenafil and iNO, incorporates assessment of 
cardiac function and may help to resolve this question (57). 
 
Cardiac function assessment might also help guide ECMO use.  In severe LV 
dysfunction and veno-arterial ECMO is appropriate to provide cardiac support and 
time for function to improve in the first days of life.  In severe ventilatory and 
oxygenation failure, where LV function is preserved, veno-venous (VV) ECMO may 
suffice. 
 
Cardiac function assessment may also inform timing of surgery in CDH.  Our 
observation that cardiac function improved at 72-120 hours in unrepaired CDH, 
supports a strategy of delayed repair to optimize cardiac function and pulmonary 
artery pressure pre-operatively (58).  Conversely, Tanaka et al have observed 
improved LV diastolic wall strain after early CDH repair on day 1 of life, suggesting 
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that early reduction of the hernia may improve LV function (59).  Comparison of 
these approaches merits further investigation.  
 
miRNA 
The miR17-92 cluster showed an abnormal expression in patients with CDH. 
miRNAs has been implicated in the development of PH particularly cluster miR17-
92(60).  
One of the pathogenetic hallmark of PH is the dysregulation expression of bone 
morphogenetic protein receptor type II (BMPR2)(61). BMPR2 regulates growth, 
differentiation, and apoptosis in a diverse number of cell lines, including 
mesenchymal and epithelial cells, acting as instructive signals during 
embryogenesis and contributing to the maintenance and repair of adult 
tissues(16,17). Mutations in the BMPR2 gene have been found in approximately 
70% of families with idiopathic PH(62,63). In the lung, BMPR-II is highly expressed 
on the vascular endothelium of the pulmonary arteries(62). Morrell et al. 
demonstrated that expression of BMPR-II is markedly reduced in the pulmonary 
vasculature of patients with mutations in the BMPR-II gene (64). BMPR-II 
expression was significantly reduced in the pulmonary vasculature of patients with 
PH in whom no mutation in the BMPR2 gene was identified suggesting that a 
critical reduction in the expression of BMPR-II may be important to the 
pathogenesis of PH, whether or not there is a mutation in the gene. Several 
miRNAs encoded by the miR17-92 were retrieved as potential regulators of it.  
Brock et al. reported that an overexpression resulted in a strong reduction of the 
BMPR2 protein (61). Some studies reported by stimulation experiments, that the 
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miR17-92 cluster is also modulated by interleukin (IL)-6, a cytokine involved in the 
pathogenesis of pulmonary hypertension. IL-6 signaling is mainly mediated by 
STAT3 (signal transducer and activator of transcription 3), the expression of STAT3 
was knocked down by small interfering RNA, which abolished the IL-6–mediated 
expression of miR17-92 (61). STAT 3 has been reported to promote lung branching 
morphogenesis, bronchiolar epithelial cell proliferation (65). STAT 3 through IL-6 
stimulates miR17-92, particularly miR17 and 20. Also, miR17 and 20 can bind 
BMPR2 and down regulate it. In our CDH population miR17 was significantly over-
expressed compared to controls. Chen et al. found that smooth muscle cell (SMC)-
specific knockout of miR17-92 attenuated hypoxia-induced PH in mice, whereas 
reconstitution of miR17-92 restored hypoxia-induced PH in these mice (60). 
Inhibition of miR17, a member of the miR17-92 cluster, induces p21 and prevents 
hypoxia-induced pulmonary hypertension (PH) (60). Our findings add further 
support to the hypothesis that miRNA 17-92 cluster is a contributor of pulmonary 
hypertension in CDH although no correlation with clinical outcomes were found. 
This suggests that miRs may represent an hallmark of PH in CDH patients but don’t 
represent a predictor of disease severity. 
 
Limitations 
CDH is a relatively rare condition limiting the sample size.  This may have 
contributed to the absence of statistically significant relationship between cardiac 
function and survival or ECMO as isolated outcomes.   Although echocardiographic 
data was collected according to an institutional protocol not all parameters could 
be analyzed in each subject, a challenge of retrospective investigation and the 
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need for optimized echocardiographic images for advanced functional analysis.  
Measurement of cardiac dimensions is particularly prone to error, which may have 
contributed to the lack of association between and left ventricular area and 
postnatal function. 
The site of arterial blood gas sampling for arterial PO2 measurement is an 
important consideration (66).  In the presence or right-to-left PDA shunting 
samples obtained from a post-ductal position such as an umbilical arterial catheter 
(nineteen cases in this cohort, 76%) may yield a higher OI than those obtained pre-
duct from the right radial artery (6 cases, 24%). 
We were unable to control for or distinguish the individual effect of therapies such 
as cardiotropes, pulmonary vasodilators and ECMO on cardiac function.  However, 
most therapies were commenced after the first echocardiograms which were 
therefore considered to reflect native function.  Longitudinal analysis of cardiac 
function, beyond the fifth day of life, was not included in this study and is an 
important area of ongoing investigation.  
No sufficient echocardiography evaluation was available for the patients from the 
miRNA group, thus no correlation between the miRNA and severity of PH and 
cardiac function were explored. Further studies are warranted to investigate the 
relation between it. 
 
Conclusions 
Infants with CDH are at risk of global RV and LV dysfunction in the early postnatal 
period.  LV systolic function correlates with prenatal lung volume and clinical 
outcome measures.  miRs may be considered hallmarks of PH, although they don’t 
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represent predictors of disease severity. These findings support routine, early and 
regular assessment of cardiac function in CDH to guide targeted therapies.  
Current and future trials incorporating this approach may lead to improved 
outcomes in CDH.  
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Figure legends: 
Figure 1: RV and LV global longitudinal strain in CDH patients in the first 48hrs of 
life 
LV, left ventricle; RV, right ventricle; GLS global longitudinal strain; dashed line 
indicates cut off values for abnormal LV ≤ - 16% and solid line indicates cut-off for 
abnormal RV GLS ≤ -14% 
 
Figure 2: LV GLS and outcomes (a) MR O:E TFLV (b) duration of intubation; (c) 
length of stay 
Figure 2a: MRI O:E TFLV vs. LV GLS 
Figure 2b: Duration of intubation vs. LV GLS 
Figure 2c: Length of stay vs. LV GLS  
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Figure 3: miRNA 17-92 cluster in CDH vs controls  
Figure a: miR17 in CDH vs controls 
Figure b: miR18a in CDH vs controls 
Figure c: miR19b in CDH vs controls 
Figure d: miR20a in CDH vs controls 
Figure e: miR19a in CDH vs controls 
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Figure 1: RV and LV global longitudinal strain in CDH patients in the first 48hrs of 
life 
 
 
LV, left ventricle; RV, right ventricle; GLS global longitudinal strain; dashed line 
indicates cut off values for abnormal LV ≤ - 16% and solid line indicates cut-off for 
abnormal RV GLS ≤ -14% 
 
Figure 2: LV GLS and outcomes (a) MR O:E TFLV (b) duration of intubation; (c) 
length of stay 
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Figure 2a: MRI O:E TFLV vs. LV GLS 
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Figure 2b: Duration of intubation vs. LV GLS 
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Figure 2c: Length of stay vs. LV GLS  
 
Figure 3: miRNA 17-92 cluster in CDH vs controls  
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Figure a: miR17 in CDH vs controls 
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Figure b: miR18a in CDH vs controls 
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Figure c: miR19b in CDH vs controls 
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Figure d: miR20a in CDH vs controls 
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Figure e: miR19a in CDH vs controls 
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Figure f: miR92 in CDH vs controls 
 
 
 
 
 
